Effect and biomarker of Nivolumab for non-small-cell lung cancer.

In recent years, immunotherapy has become an innovative technology for cancer therapy with the discovery of immunological checkpoints. It has shown great potential in a variety of advanced cancer treatments. Particularly, significant progress has been achieved in the understanding of programmed death-1/programmed death ligand-1 (PD-1/ PD-L1) pathway. Nivolumab, a human immunoglobulin (Ig)G4 PD-1 monoclonal antibody, was the first PD-1 inhibitor approved in the treatment of advanced non-small-cell lung cancer (NSCLC). Nivolumab has become a mainstay of first-line treatment of advanced/metastatic NSCLC without targetable genetic alterations. However, there are some questions in clinic that lacking of identifying biomarkers to predict the PD-1 immune checkpoint inhibition response. In this review, we summarize the results from recent clinical trials that have evaluated the nivolumab as first- or second- line treatment as monotherapy, in combination with chemotherapy and other immunotherapies. Also, we discuss the function of potential predicted biomarkers such as PD-L1 expression and tumor mutation burden in cancer treatment.

• Publication year

  2019

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2019-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BIOPHA.2019.109199PMID 31387181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

  2019cited by this paper
• Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

  2019cited by this paper
• CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

  2019cited by this paper
• Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

  2019cited by this paper
• PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

  2019cited by this paper
• First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

  2019cited by this paper
• Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

  2018cited by this paper
• Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

  2018cited by this paper
• Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

  2018cited by this paper
• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

  2018cited by this paper
• Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

  2018cited by this paper
• Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

  2018cited by this paper
• Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

  2018cited by this paper
• Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

  2018cited by this paper
• Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

  2018cited by this paper
• Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD‐1 Axis Inhibitors in Patients With Advanced Non–Small‐Cell Lung Cancer

  2018cited by this paper
• Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

  2018cited by this paper
• PD-L1 expression testing in non-small cell lung cancer

  2018cited by this paper
• Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice

  2018cited by this paper
• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  2018cited by this paper
• PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.

  2018cited by this paper
• A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

  2018cited by this paper
• Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

  2018cited by this paper
• Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

  2018cited by this paper
• Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

  2018cited by this paper
• Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.

  2018cited by this paper
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

  2017cited by this paper
• Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients

  2017cited by this paper
• MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway

  2017cited by this paper
• Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.

  2017cited by this paper
• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  2017cited by this paper
• Geography, Ethnicity or Subsistence-Specific Variations in Human Microbiome Composition and Diversity

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non‐small cell lung cancer

  2017cited by this paper
• Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

  2017cited by this paper
• First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

  2017cited by this paper
• Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

  2017cited by this paper
• Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

  2017cited by this paper
• Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma

  2017cited by this paper
• Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

  2017cited by this paper
• Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.

  2017cited by this paper
• OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

  2017cited by this paper
• Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

  2017cited by this paper
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2017cited by this paper
• Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Nivolumab in patients (pts) with advanced refractory squamous (SQ) non‐small cell lung cancer (NSCLC): 2‐year follow‐up from CheckMate 063 and exploratory cytokine profling analyses: 137O

  2016cited by this paper
• Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

  2016cited by this paper
• The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines

  2016cited by this paper
• The PI3K/AKT Pathway as a Target for Cancer Treatment.

  2016cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

  2016cited by this paper
• Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients

  2016cited by this paper
• PD‐L1 Is Upregulated by Simultaneous Amplification of the PD‐L1 and JAK2 Genes in Non–Small Cell Lung Cancer

  2016cited by this paper
• Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study

  2016cited by this paper
• Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Therapeutic Advances in Respiratory Disease

  2016cited by this paper
• Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

  2016cited by this paper
• Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications

  2015cited by this paper
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway.

  2015cited by this paper
• Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

  2015cited by this paper
• Nivolumab in melanoma: latest evidence and clinical potential

  2015cited by this paper
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2015cited by this paper
• Nivolumab for the treatment of cancer

  2015cited by this paper
• Toxicities of Immunotherapy for the Practitioner.

  2015cited by this paper
• [Melanoma: introduction and special demands on radiology].

  2015cited by this paper
• Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

  2014cited by this paper
• Growth arrest signaling of the Raf/MEK/ERK pathway in cancer

  2014cited by this paper
• PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

  2013cited by this paper
• Inflammation- and stress-related signaling pathways in hepatocarcinogenesis.

  2012cited by this paper
• Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion

  2011cited by this paper
• Cochinchina momordica seed extract induces G2/M arrest and apoptosis in human breast cancer MDA-MB-231 cells by modulating the PI3K/Akt pathway.

  2011cited by this paper
• A decade of advances in treatment for advanced non-small cell lung cancer.

  2011cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians.

  2010cited by this paper
• B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

  2008cited by this paper
• Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

  2008cited by this paper
• ZM336372, A Raf-1 Activator, Causes Suppression of Proliferation in a Human Hepatocellular Carcinoma Cell Line

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• PD‐L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding

  2007cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• The activation of Akt/PKB signaling pathway and cell survival

  2005cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

  2004cited by this paper

• PD-1 and PDL-1 Immune Checkpoint Inhibitors: Emerging Hope for the Future of Lung Cancer Immunotherapy

  2025cites this paper
• Strategy to mitigate aggregation during Protein A chromatography and low pH virus inactivation for a nivolumab biosimilar candidate.

  2025cites this paper
• Immunotherapy for lung cancer.

  2024cites this paper
• Unveiling the altered metabolic pathways induced by nivolumab in non-small cell lung cancer via GC-MS metabolomics approach coupled with multivariate analysis.

  2024cites this paper
• Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

  2023cites this paper
• A population-based nomogram for prognostic assessment in advanced lung cancer following progression with immune checkpoint inhibitor

  2023cites this paper
• PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

  2023cites this paper
• Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

  2023cites this paper
• Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances.

  2023cites this paper
• Combined Use Of Uv And Ms Data For Ich Stability-Indication Method: Quantification And Isoforms Identification Of Intact Nivolumab

  2022cites this paper
• OPA1 supports mitochondrial dynamics and immune evasion to CD8+ T cell in lung adenocarcinoma

  2022cites this paper
• Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer

  2021cites this paper
• Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors

  2021cites this paper
• Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non–small-cell lung cancer

  2021cites this paper
• Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

  2021cites this paper
• Expression of miR-92a, miR-224 and miR-25 in non-small cell lung cancer and their correlation with clinical characteristics.

  2021cites this paper
• Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC

  2021cites this paper
• Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

  2021influential citation
• Molecular Identi cation of Immunity- and Ferroptosis-related Gene Signature in Non-small Cell Lung Cancer

  2021cites this paper
• α-Mangostin reduced the viability of A594 cells in vitro by provoking ROS production through downregulation of NAMPT/NAD

  2020cites this paper
• Nivolumab Monotherapy or Combination Therapy with Ipilimumab for Lung Cancer: A meta-analysis of Randomized Controlled Trials

  2020influential citation
• Therapeutic Antibodies for the Treatment of Cancer: Cancer Immunotherapy

  2020cites this paper
• Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic

  2020cites this paper
• Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.

  2020cites this paper
• Resistance to chemoimmunotherapy in non-small-cell lung cancer

  2020cites this paper
• Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

  2020cites this paper
• Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer

  2020cites this paper
• Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies

  2020cites this paper
• Analysis of clinical features and prognostic factors of lung cancer patients: A population-based cohort study.

  2020cites this paper
• Effects of high-quality nursing care for patients with lung cancer during the perioperative period

  2019cites this paper